Pattern of tumor progression in liver cancer: The missing partner in trial design

Hepatology

Volumn 62, Issue 3, 2015, Pages 674-676

  Reig, Maria ^a,b   Bruix, Jordi ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVANIB; LINIFANIB; SORAFENIB; SUNITINIB; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER GROWTH; CLINICAL TRIAL (TOPIC); DRUG TREATMENT FAILURE; HUMAN; LIVER CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK ASSESSMENT; STUDY DESIGN; TUMOR VOLUME; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; LIVER NEOPLASMS; MALE; STATISTICS AND NUMERICAL DATA; TREATMENT WITHDRAWAL;

CARCINOMA, HEPATOCELLULAR; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; WITHHOLDING TREATMENT;

EID: 84939654350     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27881     Document Type: Article

References (8)

1. Reig M, Darnell A, Forner A, Rimola J, Ayuso C, Bruix J. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin Liver Dis 2014;34:444-455.
2. Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 1976;38:388-394.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
4. Reig M, Rimola J, Torres F, et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology 2013;58:2023-2031.
5. Iavarone M, Cabibbo G, Biolato M, Della Corte C, Maida M, Barbara M, et al. Predictors of survival of patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology 2015;62:784-791.
6. Reig M, Torres F, Rodriguez-Lope C, Forner A, LLarch N, Rimola J, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J. Hepatol 2014;61:318-324.
7. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014;63:844-855.
8. Fox EJ, Loeb LA. Cancer: one cell at a time. Nature 2014;512:143-144.